The global radiation oncology market size was estimated at USD 7,581.3 million in 2020 and is projected to reach USD 13,558.6 million by 2028, growing at a CAGR of 7.5% from 2021 to 2028. Key factors driving the market include technological advancements in radiotherapy equipment, the global rise in cancer cases, and increasing adoption of radiation therapy in oncology treatment.
Recently, in March 2025, Actinium Pharmaceuticals announced the launch of ATNM-400, an innovative radiotherapy for prostate cancer that targets non-prostate-specific membrane antigen (PSMA) pathways. The therapy utilizes the alpha-emitting radioisotope actinium-225 (Ac-225) to deliver targeted radiation treatment.
Furthermore, the radiation oncology industry is witnessing increased demand for radiotherapy due to the rising global cancer burden. According to the WHO, globally, around 19.3 million people were suffering from cancer, and 10 million died from it in 2022. Moreover, WHO in Europe estimated that there were 4.6 million new people diagnosed with various indications of cancers, such as prostate, breast, lung, colorectal, and brain, and around 2.1 million people across European countries died from the disease in 2020. As per the American Cancer Society’s 2022 report, breast cancer is the most common occurring condition, which accounts for approximately 351,400 new cases in the U.S. of invasive and non-invasive breast tumors, respectively.
In the dynamic market outlook of the radiation therapy space, key players are making strategic moves to enhance their market presence. In October 2023, Accuray Incorporated gained approval for its Tomo C radiation therapy system in China, opening new avenues for growth in the region. This regulatory milestone reflects Accuray's commitment to expanding its market reach. Similarly, in June 2023, PharmaLogic Holdings Corp. entered into a Master Services Agreement for the development and production of theranostic candidates VMT-01 and VMT-NET. These radiopharmaceuticals, currently in the research and development phase, aim to address the diagnostic and treatment needs of metastatic melanoma and neuroendocrine cancers. This strategic collaboration underscores PharmaLogic's dedication to advancing innovative solutions in the oncology space.
The market growth stage is high, at an accelerating rate of pace. The radiation therapeutic in oncology is characterized by a high degree of innovation. This can be attributed to advanced technologies and methodologies for transforming treatment practice. The market witnesses notable M&A activities by the leading players. Leading players are strategically joining forces to expand and enhance their services, gain access to new technologies, consolidate the rapidly growing market, and address the increasing strategic importance of radiotherapy.
In the radiation oncology industry, key player IBA has taken a significant step in July 2023 by partnering with Apollo Proton Cancer Centre in India. This collaboration aims to enhance the skills of oncologists in proton beam therapy through specialized training programs. This strategic move by IBA underscores the growing importance of knowledge-sharing and skill development within the radiation oncology sector. The initiative is expected to contribute to the overall advancement of proton therapy applications, potentially impacting the market dynamics positively. As a result, other industry players might consider similar partnerships or training programs to stay competitive and contribute to the overall growth and improvement of radiation oncology practices.
The market is also subject to increasing regulatory scrutiny. Radiation exposure is regulated by governmental agencies such as the FDA, the Department of Transportation (DOT), the Environmental Protection Agency (EPA), and the Nuclear Regulatory Commission (NRC). Radiation-emitting devices used in medicine are regulated by the Center for Devices and Radiologic Health (CDRH), whereas the use of radiation for medical purposes is regulated by the FDA. Radiation oncology devices are governed under the Radiation Control for Health and Safety Act, 1968.
The Code of Federal Regulations Title 21 governs the use of radiopharmaceuticals in the U.S. The diagnostic and therapeutic applications of radiopharmaceuticals are separately covered under this title in Part 315 & Part 361, respectively. In addition, the Nuclear Regulatory Commission (NRC) regulates the use of radiopharmaceuticals in 37 states. The NRC authorizes utilization and possession of radioactive source material, by product material, and special nuclear material.
CDRH governs the use of radiopharmaceuticals. In addition, it governs the use of electron-emitting products, including medical devices. However, radioisotopes that produce chemical effects, such as Ra-223, are governed by the Center for Drug Evaluation & Research, and the ones considered biologics, such as I-131 and Y-90, are used for the treatment of non-Hodgkin’s lymphoma and are governed by the Center for Biologics Evaluation and Research.
Radiation therapy has significant substitutes like surgeries and chemotherapy that improve many of the anticancer effects, but have more side effects. However, any technological advancements in radiation therapy that offer improved technology with high efficacy may be a threat to existing treatment options, such as IGRT, proton therapy, and 3D-conformity therapy, encouraging patients to shift to advanced treatment options. The lack of effective treatment options for complex cancers and increased side effects of therapies are expected to negatively impact the overall market growth.
Moreover, the industry is witnessing a growing number of geographical expansion strategies, for instance, players such as Curium in June 2021, acquired Austrin to expand its presence in Europe for its broad portfolio of life-saving diagnostic solutions. This acquisition will help the company strengthen its positron emission-tomography (PET) radiopharmaceutical business.
The external beam radiation therapy (EBRT) market, which includes linear accelerators (Linac), and compact advanced radiotherapy systems, dominated the overall market with the largest revenue share in 2024 due to increased adoption in the treatment of various types of cancers. Furthermore, EBRT products have a high ability to kill tumors in the early phases as compared to conventional therapies with fewer side effects. Moreover, rapid technological advancements and investigation of such technologies on various cancer treatments are increasing demand for LINACs and MR-LINACs, thereby contributing to the growth of the market.
Linear accelerator (Linac) uses microwave technology like radar to destroy tumor cells by delivering high-energy electrons or X-rays near the tumor region and sparing the surrounding healthy tissue. Introduction of novel linear accelerators contributes to market growth. For instance, in May 2024, Elekta announced the launch of Evo, its latest linear accelerator (linac) system. Evo features advanced high-definition, AI-enhanced imaging and is designed to support both offline and online adaptive radiation therapy, as well as enhanced standard image-guided radiation treatments. This versatile CT-Linac enables clinicians to tailor radiation therapy techniques to meet each patient's specific needs. Elekta introduced Evo at ESTRO 2024, Europe’s largest radiation oncology industry exhibition, held in Glasgow, Scotland, during the Annual Congress of the European Society for Radiotherapy and Oncology.
The IMRT segment held the largest revenue share of 24.06% in 2024, attributed to the substantial demand for treatment and increased availability of technologically advanced intensity-modulated radiotherapy (IMRT) in countries with unmet treatment needs. However, brachytherapy is estimated to be the fastest-growing segment over the forecast period due to the benefits associated with its high adoption rate and minimal risk of side effects.
3D-CRT projects radiation beams in such a way that the beams match the dimensions of the tumor and help physicians to know the exact dimensions of the tumor, which limits the damage to healthy tissues. It allows delivery of higher dose levels at the tumor site, thereby increasing its effectiveness to shrink and destroy the tumor by using a multi-leaf collimator (MLC) in a step-and-shoot technique. 3D-CRT is used to treat head & neck, liver cancer, prostate, lung, and brain cancer.
The advancements in brachytherapy provide precise and targeted dose delivery and personalized treatment options to patients. This technology is mostly used for the treatment of prostate cancer. Compared to conventional treatment techniques, its improved efficacy and reduced setup time are likely to drive the worldwide brachytherapy segment. Moreover, supportive reimbursement policies for products related to brachytherapy reduced the treatment cost, thereby encouraging patients to avail treatment. In February 2025, the Saskatchewan Cancer Agency (SCA) announced the launch of its Interstitial High-Dose-Rate (HDR) Gynecological Brachytherapy program, a specialized and highly targeted form of radiation therapy considered the gold standard for treating cervical cancer. With this program now available in Saskatchewan, patients no longer need to travel out of province to access this advanced treatment.
The EBRT segment for prostate cancer held the largest revenue share of 58.65% in 2024 and is anticipated to maintain its dominance over the forecast period. This can be attributed to the rising global cancer prevalence and increasing adoption of EBRT systems by cancer centers and hospitals. For instance, in September 2021, Unicancer acquired multiple Radixact Systems of Accuray, Inc. with ClearRT with an aim to provide personalized treatment to patients in Europe. Unicancer is a French hospital network that provides treatment to 530,000 cancer patients annually.
The market for IBRT is anticipated to witness significant growth over the forecast period due to the growing prevalence of cancer in developing countries and increased product penetration. IBRT is mostly used in conjunction with breast cancer surgery. Brachytherapy for breast tumors involves different techniques for placing devices, such as interstitial brachytherapy and intracavitary brachytherapy. The most performed technique for breast cancer is intracavitary brachytherapy. According to a study published by the National Cancer Institute (NCI) showed that whole breast irradiation (WBI) and accelerated partial-breast irradiation (APBI) lower the rate of cancer recurring in breast cancer patients.IMRT has become the standard treatment for locally advanced head and neck cancer due to its high conformality. Moreover, gynecologic cancer is mostly treated with the help of various brachytherapy techniques.
North America radiation oncology industry dominated globally in terms of revenue share of 47.16% in 2024, owing to the favorable government initiatives and availability of technologically advanced radiotherapy equipment. Furthermore, active participation of key players to increase their market share in region is fueling the market growth. For instance, in December 2021, MVision AI entered partnership with Medron Medical Systems to distribute AI radiotherapy technology of MVision in Canada. The use of AI technology provides high accuracy, leading to improved patient outcomes.
The radiation oncology industry in the U.S. benefits from strong technological innovation, high healthcare spending, and well-established cancer treatment infrastructure. Widespread adoption of advanced modalities like proton therapy and image-guided radiotherapy (IGRT) fuels demand. In addition, a rising geriatric population, increasing cancer incidence, and supportive reimbursement policies by Medicare and private insurers significantly contribute to market expansion. Active R&D and frequent clinical trials further enhance treatment precision and accessibility, making the U.S. a global leader in radiation oncology.
The radiation oncology industry in Europe is driven by universal healthcare access, rising cancer prevalence, and government funding in public hospitals. Countries are investing in upgrading linear accelerators and integrating AI into radiotherapy workflows. EU-wide collaborations in oncology research promote innovation and early technology adoption. Public awareness campaigns and national screening programs further increase early diagnosis rates, boosting demand for radiation therapy. Integration of radiology networks across borders also improves access and standardization of cancer care.
The UK radiation oncology industry is growing due to NHS investments in cancer treatment infrastructure, including modernizing radiotherapy equipment. Government-backed initiatives like the Cancer Strategy emphasize early detection and rapid access to treatment. High incidence of breast and lung cancer, paired with centralized radiology networks, supports demand for radiotherapy. Integration of AI and adaptive radiotherapy, along with strong clinical trial participation, also bolsters innovation and adoption of cutting-edge technologies across NHS trusts.
Germany’s radiation oncology industry growth is driven by its robust healthcare system, widespread access to cancer care, and heavy investment in medical technology. High per capita healthcare expenditure and a strong manufacturing base support local development and deployment of advanced radiation systems. In addition, Germany’s aging population, coupled with increasing cancer diagnoses, drives treatment demand. Public-private partnerships in oncology research and continuous upgrades in treatment planning and delivery systems fuel market expansion in this technologically advanced nation.
Asia Pacific radiation oncology industry is projected to be the fastest-growing globally over the forecast period due to improvements in healthcare infrastructure, increase in patient awareness levels, and high unmet patient needs. In addition, rising cancer burden and funding support to major players in the region are expected to offer lucrative opportunity for segment growth. According to Globocan report 2020, about 9.5 million new cancer cases were diagnosed, and 5.8 million died due to this disease in the region, increasing demand for radiotherapy to manage the impact of cancer in the countries.
China radiation oncology industry is expanding rapidly due to a rising cancer burden, large population base, and government efforts to improve oncology infrastructure. The Healthy China 2030 initiative supports investment in radiotherapy centers and training of oncologists. Urbanization and healthcare reforms have improved access to treatment. Domestic companies are also emerging with cost-effective radiotherapy solutions. Increased adoption of intensity-modulated radiation therapy (IMRT) and stereotactic body radiotherapy (SBRT) reflects technological progress and rising clinical standards.
Japan radiation oncology industry growth stems from a high elderly population, advanced medical infrastructure, and early adoption of precision radiotherapy technologies. Proton therapy is well-established and heavy government investment in cancer research accelerates development. Favorable reimbursement for advanced treatments and public awareness of early cancer detection drive clinical demand. In addition, collaboration between academia and industry supports innovation, while national health insurance ensures widespread access to sophisticated radiation oncology services.
Latin America radiation oncology industry growth is driven by rising cancer incidence, improving healthcare infrastructure, and growing public-private investment in cancer treatment. Countries like Brazil and Mexico are expanding radiotherapy centers and increasing access to IMRT and 3D conformal radiotherapy. International collaborations and training programs are improving clinical capabilities. Though limited by healthcare disparities, increased awareness and access to insurance are expanding patient access to radiation therapy across the region.
The Middle East and Africa (MEA) radiation oncology industry is witnessing growth due to government investments in healthcare modernization and an increasing focus on oncology. Gulf countries like the UAE and Saudi Arabia are establishing state-of-the-art cancer centers, while Africa is seeing support from international NGOs and partnerships. Rising cancer awareness, urbanization, and expansion of private healthcare are improving access to radiation services. However, growth is uneven, with more rapid development in wealthier nations.
The leading players in radiation oncology industry are focusing on growth strategies, such as innovations with radiotherapy, product launches, and mergers & acquisitions. For instance, in June 2022, a company pioneering the use of biology-guided radiotherapy (BgRT), RefleXion Medical announced its first symposium focused on the power of using cancer biology to direct treatment planning and delivery for personalized radiotherapy. Moreover, in October 2021, Siemens Healthineers AG in collaboration with UC Health Proton Therapy Center completed enrollment for FAST-01 of Flash Therapy for the treatment of symptomatic bone metastases.
The following are the leading companies in the radiation oncology market. These companies collectively hold the largest market share and dictate industry trends.
In April 2025, ZEISS Medical Technology reaffirmed its commitment to advancing modern oncology with the FDA’s 510(k) clearance of its INTRABEAM 700 system. This next-generation platform delivers robotic-assisted precision for intraoperative radiation therapy (IORT). Featuring a digital-first design, the INTRABEAM 700 streamlines workflows and enhances connectivity-delivering significant clinical value in neuro-oncology and breast cancer treatment.
In March 2024, AstraZeneca announced a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing next-generation radioconjugates (RCs). This acquisition represents a significant advancement in AstraZeneca’s mission to revolutionize cancer care by shifting from traditional therapies such as chemotherapy and radiotherapy to more precise, targeted treatment approaches.
In February 2023, RefleXion Medical, a therapeutic oncology company, announced that the U.S. Food and Drug Administration (FDA) granted the first marketing clearance for its SCINTIX biology-guided radiotherapy-a groundbreaking treatment designed for both early- and late-stage cancers. To highlight the significance of this advancement, the company will host a live-streamed event featuring its co-founder and CEO, who will discuss the impact of SCINTIX therapy on cancer care.
Report Attribute |
Details |
Market size value in 2025 |
USD 12.48 billion |
Revenue forecast in 2030 |
USD 21.19 billion |
Growth Rate |
CAGR of 11.17% from 2025 to 2030 |
Base year for estimation |
2024 |
Historical data |
2018 - 2023 |
Forecast period |
2025 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2030 |
Report coverage |
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
Segments covered |
Type, technology, application, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; UK; Germany; France; Spain; Italy; Denmark; Sweden, Norway; Japan; China; India; Australia; South Korea;Thailand Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
Key companies profiled |
Varian Medical Systems, Inc.; Elekta AB; Accuray Incorporated; IBA Radiopharma Solutions; BD; Isoray Medical; Mevion Medical Systems, Inc.; Nordion Inc.; NTP Radioisotopes SOC Ltd.; Curium Pharma; Viewray Technologies, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global radiation oncology market report based on type, technology, application, and region:
Type Outlook (Revenue, USD Million, 2018 - 2030)
External Beam Radiation Therapy
Linear Accelerators (Linac)
Compact advanced radiotherapy systems
Cyberknife
Gamma Knife
Tomotherapy
Proton Therapy
Cyclotron
Synchrotron
Internal Beam Radiation Therapy
Brachytherapy
Seeds
Applicators and Afterloaders
Electronic Brachytherapy
Systemic Beam Radiation Therapy
Others
Technology Outlook (Revenue, USD Million, 2018 - 2030)
External Beam Radiation Therapy
Image-Guided Radiotherapy (IGRT)
Intensity Modulated Radiotherapy (IMRT)
Stereotactic Technology
Proton Beam Therapy
3D Conformal Radiotherapy (3D CRT)
Volumetric Modulated Arc Therapy (VMAT)
Brachytherapy
Low-Dose Rate Brachytherapy
High-Dose Rate Brachytherapy
Application Outlook (Revenue, USD Million, 2018 - 2030)
External Beam Radiation Therapy
Prostate Cancer
Breast Cancer
Lung Cancer
Head and Neck Cancer
Colorectal Cancer
Others
Internal Beam Radiation Therapy
Prostate Cancer
Gynecological Cancer
Cervical Cancer
Breast Cancer
Penile Cancer
Others
Regional Outlook (Revenue, USD Million; 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
Thailand
Rest of APAC
Latin America
Brazil
Argentina
Rest of LATAM
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Rest of MEA
b. The global radiation oncology market size was estimated at USD 10.56 billion in 2024 and is expected to reach USD 12.48 billion in 2025.
b. The global radiation oncology market is expected to witness a compound annual growth rate of 11.17% from 2025 to 2030 to reach USD 21.19 billion in 2030.
b. The IMRT technology segment dominated the market for radiation oncology and accounted for the largest revenue share of 24.06% in 2024. IMRT allows a change in radiation intensity during treatment to specifically target cancer cells and limit the damage to adjoining healthy tissues.
b. Breast cancer treated using EBRT accounted for a significant share in 2024 due to high effectiveness and supporting awareness programs.
b. North America dominated the radiation oncology market in 2024 and accounted for the largest revenue share of more than 47.16%. High healthcare expenditure, advanced healthcare infrastructure, and significant R&D investments are some of the major factors contributing to the market dominance of this region.
b. Based on type, the External Beam Radiation Therapy segment held the largest share of 58.33% in 2024, owing to the relatively higher price of equipment, high installed base, lower side-effects, and ease in delivery as radiologists can control the rate of radiotherapy.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Technology
1.2.3. End Use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. Technology outlook
2.2.3. Applicationoutlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Radiation Oncology Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Rising adoption of radiotherapy
3.4.2. Technological advancements in radiotherapy
3.4.3. Rising prevalence of cancer
3.4.4. Increase in healthcare expenditure
3.4.5. Increasing application of radiopharmaceuticalsg
3.5. Market Restraint Analysis
3.5.1. Lack Of Skilled Radiotherapy Professionals
3.5.2. Inadequate Radiation Infrastructure
3.5.3. Adverse Effects Of RadiotherapyType Analysis Tools
3.5.4. Porter’s Five Forces Analysis
3.5.5. PESTEL Analysis
Chapter 4. Radiation Oncology Market: Type Estimates & Trend Analysis
4.1. Radiation Oncology Market: Type Movement Analysis
4.2. Radiation Oncology Market Estimates and Forecast, by Type
4.3. External Beam Radiation Therapy
4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.3.2. Linear Accelerators (Linac)
4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.3.3. Compact advanced radiotherapy systems
4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.3.3.2. Cyberknife
4.3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.3.3.3. Gamma Knife
4.3.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.3.3.4. Tomotherapy
4.3.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.3.4. Proton Therapy
4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.3.4.2. Cyclotron
4.3.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.3.4.3. Synchrotron
4.3.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4. Internal Beam Radiation Therapy
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Brachytherapy
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.2. Seeds
4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.3. Applicators and After loaders
4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.4. Electronic Brachytherapy
4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Systemic Beam Radiation Therapy
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Others
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Radiation Oncology Market: Technology Estimates & Trend Analysis
5.1. Radiation Oncology Market: Technology Movement Analysis
5.2. Radiation Oncology Market Estimates and Forecast, by Technology
5.3. External Beam Radiation Therapy
5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.3.2. Image-Guided Radiotherapy (IGRT)
5.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.3.3. Intensity Modulated Radiotherapy (IMRT)
5.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.3.4. Stereotactic Technology
5.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.3.5. Proton Beam Therapy
5.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.3.6. 3D Conformal Radiotherapy (3D CRT)
5.3.7. Volumetric Modulated Arc Therapy (VMAT)
5.3.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4. Brachytherapy
5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Low-Dose Rate Brachytherapy
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. High-Dose Rate Brachytherapy
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Radiation Oncology Market: Application Estimates & Trend Analysis
6.1. Radiation Oncology Market: Application Movement Analysis
6.2. Radiation Oncology Market Estimates and Forecast, by End Use
6.3. External Beam Radiation Therapy
6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.2. Prostate Cancer
6.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.3. Breast Cancer
6.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.4. Lung Cancer
6.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.5. Head and Neck Cancer
6.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.6. Colorectal Cancer
6.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.7. Others
6.3.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4. Internal Beam Radiation Therapy
6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Prostate Cancer
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Breast Cancer
6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Lung Cancer
6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.5. Head and Neck Cancer
6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.6. Colorectal Cancer
6.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.7. Others
6.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Radiation Oncology Market: Regional Estimates & Trend Analysis
7.1. Radiation Oncology Market Share By Region, 2024 & 2030
7.2. Regional Market Share Analysis, 2024 & 2030
7.3. Regional Market Dashboard
7.4. Global Regional Market Snapshot
7.5. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.6. North America
7.6.1. North America Radiation Oncology Market, 2018 - 2030 (USD Million)
7.6.2. U.S.
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. U.S. Radiation Oncology Market, 2018 - 2030 (USD Million)
7.6.3. Canada
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. Canada Radiation Oncology Market, 2018 - 2030 (USD Million)
7.6.4. Mexico
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. Mexico Radiation Oncology Market, 2018 - 2030 (USD Million)
7.7. Europe
7.7.1. Europe Radiation Oncology Market, 2018 - 2030 (USD Million)
7.7.2. UK
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Framework
7.7.2.4. UK Radiation Oncology Market, 2018 - 2030 (USD Million)
7.7.3. Germany
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Framework
7.7.3.4. Germany Radiation Oncology Market, 2018 - 2030 (USD Million)
7.7.4. France
7.7.4.1. Key Country Dynamics
7.7.4.2. Competitive Scenario
7.7.4.3. Regulatory Framework
7.7.4.4. France Radiation Oncology Market, 2018 - 2030 (USD Million)
7.7.5. Italy
7.7.5.1. Key Country Dynamics
7.7.5.2. Competitive Scenario
7.7.5.3. Regulatory Framework
7.7.5.4. Italy Radiation Oncology Market, 2018 - 2030 (USD Million)
7.7.6. Spain
7.7.6.1. Key Country Dynamics
7.7.6.2. Competitive Scenario
7.7.6.3. Regulatory Framework
7.7.6.4. Spain Radiation Oncology Market, 2018 - 2030 (USD Million)
7.7.7. Denmark
7.7.7.1. Key Country Dynamics
7.7.7.2. Competitive Scenario
7.7.7.3. Regulatory Framework
7.7.7.4. Denmark Radiation Oncology Market, 2018 - 2030 (USD Million)
7.7.8. Sweden
7.7.8.1. Key Country Dynamics
7.7.8.2. Competitive Scenario
7.7.8.3. Regulatory Framework
7.7.8.4. Sweden Radiation Oncology Market, 2018 - 2030 (USD Million)
7.7.9. Norway
7.7.9.1. Key Country Dynamics
7.7.9.2. Competitive Scenario
7.7.9.3. Regulatory Framework
7.7.9.4. Norway Radiation Oncology Market, 2018 - 2030 (USD Million)
7.8. Asia Pacific
7.8.1. Asia Pacific Radiation Oncology Market, 2018 - 2030 (USD Million)
7.8.2. Japan
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Framework
7.8.2.4. Japan Radiation Oncology Market, 2018 - 2030 (USD Million)
7.8.3. China
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Framework
7.8.3.4. China Radiation Oncology Market, 2018 - 2030 (USD Million)
7.8.4. India
7.8.4.1. Key Country Dynamics
7.8.4.2. Competitive Scenario
7.8.4.3. Regulatory Framework
7.8.4.4. India Radiation Oncology Market, 2018 - 2030 (USD Million)
7.8.5. Australia
7.8.5.1. Key Country Dynamics
7.8.5.2. Competitive Scenario
7.8.5.3. Regulatory Framework
7.8.5.4. Australia Radiation Oncology Market, 2018 - 2030 (USD Million)
7.8.6. Thailand
7.8.6.1. Key Country Dynamics
7.8.6.2. Competitive Scenario
7.8.6.3. Regulatory Framework
7.8.6.4. Thailand Radiation Oncology Market, 2018 - 2030 (USD Million)
7.8.7. South Korea
7.8.7.1. Key Country Dynamics
7.8.7.2. Competitive Scenario
7.8.7.3. Regulatory Framework
7.8.7.4. South Korea Radiation Oncology Market, 2018 - 2030 (USD Million)
7.9. Latin America
7.9.1. Latin America Radiation Oncology Market, 2018 - 2030 (USD Million)
7.9.2. Brazil
7.9.2.1. Key Country Dynamics
7.9.2.2. Competitive Scenario
7.9.2.3. Regulatory Framework
7.9.2.4. Brazil Radiation Oncology Market, 2018 - 2030 (USD Million)
7.9.3. Argentina
7.9.3.1. Key Country Dynamics
7.9.3.2. Competitive Scenario
7.9.3.3. Regulatory Framework
7.9.3.4. Argentina Radiation Oncology Market, 2018 - 2030 (USD Million)
7.10. MEA
7.10.1. MEA Radiation Oncology Market, 2018 - 2030 (USD Million)
7.10.2. South Africa
7.10.2.1. Key Country Dynamics
7.10.2.2. Competitive Scenario
7.10.2.3. Regulatory Framework
7.10.2.4. South Africa Radiation Oncology Market, 2018 - 2030 (USD Million)
7.10.3. Saudi Arabia
7.10.3.1. Key Country Dynamics
7.10.3.2. Competitive Scenario
7.10.3.3. Regulatory Framework
7.10.3.4. Saudi Arabia Radiation Oncology Market, 2018 - 2030 (USD Million)
7.10.4. UAE
7.10.4.1. Key Country Dynamics
7.10.4.2. Competitive Scenario
7.10.4.3. Regulatory Framework
7.10.4.4. UAE Radiation Oncology Market, 2018 - 2030 (USD Million)
7.10.5. Kuwait
7.10.5.1. Key Country Dynamics
7.10.5.2. Competitive Scenario
7.10.5.3. Regulatory Framework
7.10.5.4. Kuwait Radiation Oncology Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company Categorization
8.3. Strategy Mapping
8.4. Company Market Share Analysis, 2024
8.5. Company Profiles
8.5.1. Varian Medical Systems, Inc.
8.5.1.1. Overview
8.5.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Elekta AB
8.5.2.1. Overview
8.5.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Accuray Incorporated
8.5.3.1. Overview
8.5.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. IBA Radiopharma Solutions
8.5.4.1. Overview
8.5.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. BD (Becton, Dickinson and Company)
8.5.5.1. Overview
8.5.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Isoray Inc.
8.5.6.1. Overview
8.5.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Mevion Medical Systems
8.5.7.1. Overview
8.5.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Nordion, Inc.
8.5.8.1. Overview
8.5.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. NTP Radioisotopes SOC Ltd.
8.5.9.1. Overview
8.5.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Curium
8.5.10.1. Overview
8.5.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
8.5.11. ViewRay Technologies, Inc.
8.5.11.1. Overview
8.5.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.5.11.3. Product Benchmarking
8.5.11.4. Strategic Initiatives
List of Tables
Table 1 List of abbreviations
Table 2 Global Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 3 Global Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 4 Global Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 5 Global Radiation Oncology Market, by Region, 2018 - 2030 (USD Million)
Table 6 North America Radiation Oncology Market, by Country, 2018 - 2030 (USD Million)
Table 7 North America Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 8 North America Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 9 North America Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 10 U.S. Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 11 U.S. Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 12 U.S. Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 13 Canada Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 14 Canada Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 15 Canada Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 16 Europe Radiation Oncology Market, by Country, 2018 - 2030 (USD Million)
Table 17 Europe Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 18 Europe America Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 19 Europe America Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 20 UK Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 21 UK Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 22 UK Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 23 Germany Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 24 Germany Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 25 Germany Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 26 France Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 27 France Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 28 France Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 29 Italy Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 30 Italy Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 31 Italy Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 32 Spain Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 33 Spain Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 34 Spain Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 35 Denmark Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 36 Denmark Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 37 Denmark Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 38 Denmark Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 39 Sweden Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 40 Sweden Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 41 Sweden Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 42 Norway Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 43 Norway Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 44 Norway Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 45 Asia Pacific Radiation Oncology Market, by Country, 2018 - 2030 (USD Million)
Table 46 Asia Pacific Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 47 Asia Pacific Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 48 Asia Pacific Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 49 Japan Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 50 Japan Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 51 Japan Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 52 China Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 53 China Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 54 China Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 55 India Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 56 India Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 57 India Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 58 Australia Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 59 Australia Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 60 Australia Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 61 Thailand Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 62 Thailand Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 63 Thailand Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 64 South Korea Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 65 South Korea Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 66 South Korea Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 67 Latin America Radiation Oncology Market, by Country, 2018 - 2030 (USD Million)
Table 68 Latin America Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 69 Latin America Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 70 Latin America Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 71 Brazil Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 72 Brazil Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 73 Brazil Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 74 Mexico Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 75 Mexico Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 76 Mexico Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 77 Argentina Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 78 Argentina Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 79 Argentina Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 80 Middle East & Africa Radiation Oncology Market, by Country, 2018 - 2030 (USD Million)
Table 81 Middle East & Africa Radiation Oncology Market, by type, 2018 - 2030 (USD Million)
Table 82 Middle East & Africa Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 83 Middle East & Africa Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 84 South Africa Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 85 South Africa Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 86 South Africa Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 88 Saudi Arabia Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 89 audi Arabia Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 90 UAE Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 91 UAE Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 92 UAE Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
Table 93 Kuwait Radiation Oncology Market, by Type, 2018 - 2030 (USD Million)
Table 94 Kuwait Radiation Oncology Market, by Technology, 2018 - 2030 (USD Million)
Table 95 Kuwait Radiation Oncology Market, by End-use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 Market formulation & validation
Fig. 7 Radiation Oncology Market segmentation
Fig. 8 Market snapshot, 2024
Fig. 9 Market trends & outlook
Fig. 10 Market driver relevance analysis (current & future impact)
Fig. 11 Market restraint relevance analysis (current & future impact)
Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
Fig. 13 Porter’s five forces analysis
Fig. 14 Radiation oncology market: Type movement analysis
Fig. 15 Radiation oncology market: Type outlook and key takeaways
Fig. 16 External Beam Radiation Therapy market estimates and forecast, 2018 - 2030
Fig. 17 Linear Accelerators (Linac) market estimates and forecast, 2018 - 2030
Fig. 18 Compact advanced radiotherapy systems market estimates and forecast, 2018 - 2030
Fig. 19 Cyberknife market estimates and forecast, 2018 - 2030
Fig. 20 Gamma Knife market estimates and forecast, 2018 - 2030
Fig. 21 Tomotherapy market estimates and forecast, 2018 - 2030
Fig. 22 Proton Therapy market estimates and forecast, 2018 - 2030
Fig. 23 Cyclotron market estimates and forecast, 2018 - 2030
Fig. 24 Synchrotron market estimates and forecast, 2018 - 2030
Fig. 25 Internal Beam Radiation Therapy market estimates and forecast, 2018 - 2030
Fig. 26 Brachytherapy market estimates and forecast, 2018 - 2030
Fig. 27 Seeds market estimates and forecast, 2018 - 2030
Fig. 28 Applicators and After loaders market estimates and forecast, 2018 - 2030
Fig. 29 Electronic Brachytherapy market estimates and forecast, 2018 - 2030
Fig. 30 Systemic Beam Radiation Therapy market estimates and forecast, 2018 - 2030
Fig. 31 Others market estimates and forecast, 2018 - 2030
Fig. 32 Radiation oncology market: Technology movement analysis
Fig. 33 Radiation oncology market: Technology outlook and key takeaways
Fig. 34 External Beam Radiation Therapy market estimates and forecast, 2018 - 2030
Fig. 35 Image-Guided Radiotherapy (IGRT) market estimates and forecast, 2018 - 2030
Fig. 36 Intensity Modulated Radiotherapy (IMRT) market estimates and forecast, 2018 - 2030
Fig. 37 Stereotactic Technology market estimates and forecast, 2018 - 2030
Fig. 38 Proton Beam Therapy market estimates and forecast, 2018 - 2030
Fig. 39 3D Conformal Radiotherapy (3D CRT) market estimates and forecast, 2018 - 2030
Fig. 40 Volumetric Modulated Arc Therapy (VMAT) market estimates and forecast, 2018 - 2030
Fig. 41 Brachytherapy market estimates and forecast, 2018 - 2030
Fig. 42 Low-Dose Rate Brachytherapy market estimates and forecast, 2018 - 2030
Fig. 43 High-Dose Rate Brachytherapy market estimates and forecast, 2018 - 2030
Fig. 44 Radiation oncology market: Application movement analysis
Fig. 45 Radiation oncology market: Application outlook and key takeaways
Fig. 46 External Beam Radiation Therapy market estimates and forecast, 2018 - 2030
Fig. 47 Prostate Cancer market estimates and forecast, 2018 - 2030
Fig. 48 Breast Cancer market estimates and forecast, 2018 - 2030
Fig. 49 Lung Cancer market estimates and forecast, 2018 - 2030
Fig. 50 Head and Neck Cancer market estimates and forecast, 2018 - 2030
Fig. 51 Colorectal Cancer market estimates and forecast, 2018 - 2030
Fig. 52 Others market estimates and forecast, 2018 - 2030
Fig. 53 Internal Beam Radiation Therapy market estimates and forecast, 2018 - 2030
Fig. 54 Prostate Cancer market estimates and forecast, 2018 - 2030
Fig. 55 Gynecological Cancer market estimates and forecast, 2018 - 2030
Fig. 56 Cervical Cancer market estimates and forecast, 2018 - 2030
Fig. 57 Breast Cancer market estimates and forecast, 2018 - 2030
Fig. 58 Penile Cancer market estimates and forecast, 2018 - 2030
Fig. 59 Others market estimates and forecast, 2018 - 2030
Fig. 60 Regional outlook, 2024 & 2030
Fig. 61 Global Radiation Oncology Market: Region movement analysis
Fig. 62 North America Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 63 U.S. Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 64 Canada Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 65 Mexico Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 66 Europe Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 67 Germany Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 68 UK Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 69 France Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 70 Italy Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 71 Spain Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 72 Denmark Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 73 Sweden Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 74 Norway Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 75 Asia Pacific Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 76 Japan Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 77 China Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 78 India Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 79 Australia Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 80 South Korea Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 81 Thailand Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 82 Latin America Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 83 Brazil Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 84 Argentina Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 85 Middle East and Africa Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 86 South Africa Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 87 Saudi Arabia Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 88 UAE Radiation Oncology Market, 2018 - 2030 (USD Million)
Fig. 89 Kuwait Radiation Oncology Market, 2018 - 2030 (USD Million)
Market Segmentation
Report content
Qualitative Analysis
Quantitative Analysis
Research Methodology
Grand View Research employs a comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecast possible. The company utilizes a combination of bottom-up and top-down approaches for segmenting and estimating quantitative aspects of the market. In Addition, a recurring theme prevalent across all our research reports is data triangulation that looks market from three different perspectives. Critical elements of the methodology employed for all our studies include:
Preliminary data mining
Raw market data is obtained and collated on a broad front. Data is continuously filtered to ensure that only validated and authenticated sources are considered. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. For a comprehensive understanding of the market, it is essential to understand the complete value chain, and in order to facilitate this; we collect data from raw material suppliers, distributors as well as buyers.
Technical issues and trends are obtained from surveys, technical symposia, and trade journals. Technical data is also gathered from an intellectual property perspective, focusing on white space and freedom of movement. Industry dynamics with respect to drivers, restraints, pricing trends are also gathered. As a result, the material developed contains a wide range of original data that is then further cross-validated and authenticated with published sources.
Statistical model
Our market estimates and forecasts are derived through simulation models. A unique model is created customized for each study. Gathered information for market dynamics, technology landscape, application development, and pricing trends are fed into the model and analyzed simultaneously. These factors are studied on a comparative basis, and their impact over the forecast period is quantified with the help of correlation, regression, and time series analysis. Market forecasting is performed via a combination of economic tools, technological analysis, industry experience, and domain expertise.
Econometric models are generally used for short-term forecasting, while technological market models are used for long-term forecasting. These are based on an amalgamation of the technology landscape, regulatory frameworks, economic outlook, and business principles. A bottom-up approach to market estimation is preferred, with key regional markets analyzed as separate entities and integration of data to obtain global estimates. This is critical for a deep understanding of the industry as well as ensuring minimal errors. Some of the parameters considered for forecasting include:
• Market drivers and restraints, along with their current and expected impact
• Raw material scenario and supply v/s price trends
• Regulatory scenario and expected developments
• Current capacity and expected capacity additions up to 2030
We assign weights to these parameters and quantify their market impact using weighted average analysis, to derive an expected market growth rate.
Primary validation
This is the final step in estimating and forecasting for our reports. Exhaustive primary interviews are conducted, face to face as well as over the phone to validate our findings and assumptions used to obtain them. Interviewees are approached from leading companies across the value chain including suppliers, technology providers, domain experts, and buyers so as to ensure a holistic and unbiased picture of the market. These interviews are conducted across the globe, with language barriers overcome with the aid of local staff and interpreters. Primary interviews not only help in data validation but also provide critical insights into the market, current business scenario, and future expectations and enhance the quality of our reports. All our estimates and forecast are verified through exhaustive primary research with Key Industry Participants (KIPs) which typically include:
• Market-leading companies
• Raw material suppliers
• Product distributors
• Buyers
The key objectives of primary research are as follows:
• To validate our data in terms of accuracy and acceptability
• To gain an insight in to the current market and future expectations
Data Collection Matrix
Perspective |
Primary research |
Secondary research |
Supply-side |
|
|
Demand-side |
|
|
Industry Analysis Matrix
Qualitative analysis |
Quantitative analysis |
|
|
NEED A CUSTOM REPORT?
We offer custom report options, including stand-alone sections and country-level data. Special pricing is available for start-ups and universities.
Request CustomizationWe are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."